AI Terminal
Lifecare ASA
Report Publication Announcement • Apr 23, 2025
3654_rns_2025-04-23_9c833b5e-da03-47d4-8c69-705cf664c0a4.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
LIFECARE ASA: UPDATED COMPANY PRESENTATION
Bergen, Norway, 23 April 2025 - Lifecare ASA (LIFE), a medtech company developing next generation continuous glucose monitoring (CGM) solutions for diabetes management, today publishes an updated company presentation articulating the company's long-term value creation opportunity.
The presentation is attached and available at: https://lifecare.no/investor/
Key highlights from the presentation:
Diabetes is a trillion-dollar global healthcare challenge
- CGMs the fastest growing diabetes tech segment, representing a USD 30 billion market opportunity
- Within CGMs, implantable solutions represent a USD 5 billion potential market
Strong value drivers in place 2025-2028
- Set to capitalize on "second mover" advantage, leveraging first mover regulatory approvals in the US
- Capital efficient path to commercialization with partner-led go-to-market strategy and minimal additional R&D
- Near-term value inflection points including veterinary market launch late 2025, CE mark in 2026, and European human market launch in 2027
Significant value creation potential
- Peak revenue potential of USD 1 billion + on realistic market assumptions
- Revenue sustainable at high levels long-term assuming conservative market share in a growing market
- EBITDA margin of 35%+
About us
Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.
PRESS RELEASE 23 April 2025 07:00:00 CEST
Contacts
For further information, please contact:
Joacim Holter, CEO, [email protected], +47 40 05 90 40
Renete Kaarvik, CFO, [email protected], +47 94 83 82 42